Combining metabolic reprogramming strategies that target lactylation with small molecule inhibitors of immunosuppressive pathways, such as indoleamine 2,3-dioxygenase (IDO) inhibitors, presents a promising therapeutic approach to overcoming resistance to immunotherapy in prostate cancer 8. This evidence concerns the gene IDO1 and prostate cancer.